Terapia de indução com alentuzumabe em receptores de transplante renal

INTRODUCTION: Induction therapy has been used in sensitized patients, re-transplants, and in patients who have high risk to delayed graft function (DGF) after renal transplantation. METHODS: Retrospective study with aim to compare transplant endpoints between recipients of deceased donors which have...

Descripción completa

Detalles Bibliográficos
Autores: Sampaio, Edison Luiz Mandia [UNIFESP], Freitas, Tainá Veras de Sandes [UNIFESP], Galante, Nelson Zocoler [UNIFESP], Park, Sung In [UNIFESP], Harada, Kelly Miyuki [UNIFESP], Haolla, Filipe Augusto Bettencourt [UNIFESP], Felipe, Claudia Rosso [UNIFESP], Troconis, Paul Henri Clesca [UNIFESP], Franco, Marcello Fabiano de [UNIFESP], Tedesco-Silva Junior, Hélio [UNIFESP], Pestana, Jose Osmar Medina [UNIFESP]
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2010
País:Brasil
Institución:Universidade Federal de São Paulo (UNIFESP)
Repositorio:Repositório Institucional da UNIFESP
Idioma:portugués
OAI Identifier:oai:repositorio.unifesp.br:11600/5656
Acceso en línea:http://dx.doi.org/10.1590/S0101-28002010000100015
http://repositorio.unifesp.br/handle/11600/5656
Access Level:acceso abierto
Palabra clave:kidney transplantation
immunosuppressive agents
monoclonial antibodies
transplante de rim
imunossupressão
anticorpos monoclonais
Descripción
Sumario:INTRODUCTION: Induction therapy has been used in sensitized patients, re-transplants, and in patients who have high risk to delayed graft function (DGF) after renal transplantation. METHODS: Retrospective study with aim to compare transplant endpoints between recipients of deceased donors which have received induction with alemtuzumab (n = 9) versus thymoglobulin (n = 18). Patients were matched for age, duration of dialysis treatment and cold ischemia time. RESULTS: There were no differences at demographic characteristics. All patients received kidney grafts from deceased donors and 67% of these donors met the expanded criteria. The incidence of DFG was similar in alemtuzumab and thymoglobulin groups, 55% and 56%. At 12 months, rates of rejection free survival (67% versus 89%, p = 0,13), graft survival (62,5% versus 76,6%; p = 0,73), graft with death censored (62,5% versus 76,6%; p = 0,82) and patient survival (83,3% versus 81,2%; p = 0,63) were similar between the two groups. Viral infections and renal function were similar between groups. At the end of the first month, alemtuzumab patients displayed a fewer lymphocyte number (135 ± 78 versus 263 ± 112 N/mm³, p < 0,05) followed by a more rapid recovery after 3 months (day 90: 683 ± 367 versus 282 ± 72 N/mm³; p < 0,05). Cost associated with alemtuzumab and thymoglobulin inductions therapies were R$ 1,388.00 and R$ 7,398.00. CONCLUSION: In this cohort of patients, alemtuzumab induction showed efficacy and safety comparable to thymoglobulin but with significant cost reduction.

Similares en LA Referencia